- Home
- RMAX vs TARA Comparison
RMAX vs TARA Comparison
Compare RMAX & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMAX
- TARA
- Stock Information
- Founded
- RMAX 1973
- TARA N/A
- Country
- RMAX United States
- TARA United States
- Employees
- RMAX N/A
- TARA N/A
- Industry
- RMAX Real Estate
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RMAX Finance
- TARA Health Care
- Exchange
- RMAX Nasdaq
- TARA Nasdaq
- Market Cap
- RMAX 151.2M
- TARA 165.5M
- IPO Year
- RMAX 2013
- TARA N/A
- Fundamental
- Price
- RMAX $8.18
- TARA $7.42
- Analyst Decision
- RMAX Hold
- TARA Strong Buy
- Analyst Count
- RMAX 1
- TARA 7
- Target Price
- RMAX $9.00
- TARA $20.33
- AVG Volume (30 Days)
- RMAX 186.7K
- TARA 626.4K
- Earning Date
- RMAX 10-30-2025
- TARA 11-10-2025
- Dividend Yield
- RMAX N/A
- TARA N/A
- EPS Growth
- RMAX N/A
- TARA N/A
- EPS
- RMAX 0.62
- TARA N/A
- Revenue
- RMAX $292,931,000.00
- TARA N/A
- Revenue This Year
- RMAX N/A
- TARA N/A
- Revenue Next Year
- RMAX $0.94
- TARA N/A
- P/E Ratio
- RMAX $13.18
- TARA N/A
- Revenue Growth
- RMAX N/A
- TARA N/A
- 52 Week Low
- RMAX $6.90
- TARA $2.36
- 52 Week High
- RMAX $14.31
- TARA $10.48
- Technical
- Relative Strength Index (RSI)
- RMAX 53.71
- TARA 76.46
- Support Level
- RMAX $7.25
- TARA $5.00
- Resistance Level
- RMAX $7.73
- TARA $6.85
- Average True Range (ATR)
- RMAX 0.27
- TARA 0.56
- MACD
- RMAX 0.07
- TARA 0.23
- Stochastic Oscillator
- RMAX 87.56
- TARA 87.60
About RMAX RE/MAX Holdings Inc.
RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).